Private Placement Form 8 K

Sale of Series F Convertible Preferred Stock

As previously reported on a Current Report on Form 8-K filed on June 30, 2022, the Company entered into a Securities Purchase Agreement, dated June 26, 2022 (the "Original SPA"), as subsequently amended by the Series F SPA Amendment Agreement dated February 8, 2024 and the Series F SPA Amendment Agreement dated July 25, 2024 (the "Series F Amendment Agreements", and together with the Original SPA, the "SPA"), with Alpha Capital Anstalt ("Alpha"), pursuant to which Alpha purchased 10,000 shares of the Company's Series F 5% Convertible Preferred Stock (the "Series F Convertible Preferred") and a warrant to purchase 5,212,510 shares of the Company's Common Stock. Pursuant to the terms of the SPA, Alpha had the right to purchase up to an aggregate of $25,000,000 stated value of the Series F Convertible Preferred and accompanying warrants (the "Additional Investment Right"), at a purchase price equal to the volume-weighted average prices ("VWAPs") of the Company's common stock for three trading days prior to the date Alpha gives notice to the Company that it will exercise its Additional Investment Right.

On August 27, 2024, Alpha exercised its Additional Investment Right for the aggregate purchase of 500 shares of Series F Convertible Preferred convertible into 1,238,237 shares of Common Stock, in the aggregate, at a conversion price of $0.4038 and warrants to purchase up to 1,238,237 shares of Common Stock at an exercise price of $0.4038 per share for an aggregate purchase price of $500,000. The Warrants will be immediately exercisable upon issuance and have a three-year term.